Real‐world effectiveness and safety of oral semaglutide in people living with type 2 diabetes: A nationwide multicentre retrospective observational study (ENDO2S‐RWD)

Type 2 diabetes guidelines recommend glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and/or sodium-glucose co-transporter-2 inhibitors for people living with type 2 diabetes (PLWT2D) with an established or high risk of cardiovascular disease and/or renal disease, regardless of glycated haemoglobin (HbA1c) levels.1-3 Semaglutide is the first and only GLP-1 RA available for oral use. Despite its proven safety and efficacy in randomized clinical trials,4, 5 insights into its real-world use in clinical settings are needed.6We designed the ENDOcrinology Oral Sema Real-World Data (ENDO2S-RWD) study to evaluate the effectiveness, safety and tolerability of oral semaglutide in a large cohort of PLWT2D in Spain. We assessed the factors associated with the clinical response and drug persistence.